Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study

被引：9

作者：

Batinic, Ana ^{[1
]}

Sutlovic, Davorka ^{[2
,3
]}

Kuret, Sendi ^{[2
]}

Matana, Antonela ^{[2
]}

Kumric, Marko ^{[4
]}

Bozic, Josko ^{[4
]}

Dujic, Zeljko ^{[5
]}

机构：

[1] Pharm Split Dalmatia Cty, Split 21000, Croatia

[2] Univ Split, Univ Dept Hlth Studies, Split 21000, Croatia

[3] Univ Split, Sch Med, Dept Toxicol & Pharmacogenet, Split 21000, Croatia

[4] Univ Split, Sch Med, Dept Pathophysiol, Split 21000, Croatia

[5] Univ Split, Sch Med, Dept Integrat Physiol, Split 21000, Croatia

来源：

PHARMACEUTICALS | 2023年 / 16卷 / 05期

关键词：

cannabidiol; blood pressure; CYP P450 genes; GC-MS analysis; SNP genotyping; CANNABIDIOL; EPILEPSY;

D O I：

10.3390/ph16050645

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Cannabidiol (CBD) is a non-psychoactive cannabinoid, and available evidence suggests potential efficacy in the treatment of many disorders. DehydraTECH (TM) 2.0 CBD is a patented capsule formulation that improves the bioabsorption of CBD. We sought to compare the effects of CBD and DehydraTECH (TM) 2.0 CBD based on polymorphisms in CYP P450 genes and investigate the effects of a single CBD dose on blood pressure. In a randomized and double-blinded order, 12 females and 12 males with reported hypertension were given either placebo capsules or DehydraTECH (TM) 2.0 CBD (300 mg of CBD, each). Blood pressure and heart rate were measured during 3 h, and blood and urine samples were collected. In the first 20 min following the dose, there was a greater reduction in diastolic blood pressure (p = 0.025) and mean arterial pressure MAP (p = 0.056) with DehydraTECH (TM) 2.0 CBD, which was probably due to its greater CBD bioavailability. In the CYP2C9*2*3 enzyme, subjects with the poor metabolizer (PM) phenotype had higher plasma CBD concentrations. Both CYP2C19*2 (p = 0.037) and CYP2C19*17 (p = 0.022) were negatively associated with urinary CBD levels (beta = -0.489 for CYP2C19*2 and beta = -0.494 for CYP2C19*17). Further research is required to establish the impact of CYP P450 enzymes and the identification of metabolizer phenotype for the optimization of CBD formulations.

引用

页数：18